Dr. Lopez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-6594Fax+1 503-494-3257- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1995 - 1998
University of California (San Francisco)Residency, Internal Medicine, 1991 - 1994- University of California San Francisco School of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1992 - Present
OR State Medical License 2001 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer Start of enrollment: 2019 Aug 01
- NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer Start of enrollment: 2021 May 27
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Accessible high-throughput single-cell whole-genome sequencing with paired chromatin accessibility.Konstantin Queitsch, Travis W Moore, Brendan L O'Connell, Ruth V Nichols, John L Muschler, Dove Keith, Charles Lopez, Rosalie C Sears, Gordon B Mills, Galip Gürkan Yar...> ;Cell Reports Methods. 2023 Nov 20
- 5 citationsAtezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.Ko, A., Kim, K., Siveke, J., Lopez, C., Lacy, J., O'Reilly, E., Macarulla, T., Manji, G., Lee, J., Ajani, J., Alsina Maqueda, M., Rha, S., Lau, J., Al-Sakaff, N., Alle...> ;The Oncologist. 2023 Jun 2
- 1 citationsEfficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 stud...Fortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, Mikhail Dvorkin, Charles D Lopez, Jean-Philippe Metges, Antonio Sánchez Ruiz, Mariona Calvo, Andrew H Strickland...> ;Cancer Medicine. 2023 Jun 1
- Join now to see all
Journal Articles
- Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal AdenocarcinomaBrett Sheppard, Charles D Lopez, Zipei Feng, Clinical Cancer Research
Grant Support
- Mechanisms Linking ASPP2 To The RB/E2F And P53 PathwaysNational Cancer Institute2004–2008
- P53 And UV Regulation Of P53 Binding Protein Bbp/53bp2National Cancer Institute2001–2004
- P53 And UV Regulation Of P53 Binding Protein Bbp/53bp2National Cancer Institute2000–2001
Professional Memberships
- Member
Hospital Affiliations
Portland HCSPortland, Oregon
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
